



ALK
Investor Relations Department
BÃge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

OMX: ALKB

Last Trade:	986.00
Trade Time:	4:59 PM ET Sep 25, 2017
Change:	-4.00 ↓ (-0.404%)
Day Range	985.00 - 995.00
52-Week Range	839.00 - 1133.00
Volume	1,155,200

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

Sep 21, 2017

[ALK acts on French injunction by accelerating investments in its quality system at the French manufacturing facility](#)

Sep 14, 2017

[Successful Phase III trial for ALK's tree allergy SLIT-tablet](#)

Sep 4, 2017

[Report on transactions with ALK-Abell A/S B-shares and associated securities by managerial staff](#)

Aug 21, 2017

[ALK to accelerate launches of ODACTRA™ in the USA / ACARIZAX® in Canada](#)

Aug 16, 2017

[Six-month interim report \(Q2\) 2017](#)

Upcoming Events [\[View all \]](#)

Nov 10, 2017

[Nine-month interim report \(Q3\) 2017](#)